TrialBreast cancer research and treatment2021

ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.

Emre Koca et al.PubMed ↗Publisher ↗

No numbers read from the abstract.